Oncologic Hormonal Therapy
Key Points
- Hormonal therapy in oncology suppresses hormone-driven tumor growth rather than replacing hormones.
- Antiestrogens and SERDs are used for hormone-receptor-positive breast cancer.
- Aromatase inhibitors are primarily used in postmenopausal estrogen-receptor-positive breast cancer.
- Antiandrogens are used in prostate cancer and require liver-toxicity monitoring.
- Tamoxifen is contraindicated with coumarin-type anticoagulants and in patients with prior DVT or PE.
Mechanism and Classification
Hormone-dependent tumors rely on estrogen or androgen signaling for proliferation. Oncologic hormonal therapies suppress this signaling by blocking receptors or reducing hormone production.
- Antiestrogens/SERDs: Block or downregulate estrogen receptors in hormone-receptor-positive breast tumors.
- Aromatase inhibitors: Inhibit peripheral conversion to estrogen by blocking aromatase in adipose tissue.
- Antiandrogens: Block androgen receptors in prostate tumors.
Common Drugs
| Class | Examples | Typical Use Pattern |
|---|---|---|
| Antiestrogens/SERDs | Tamoxifen, fulvestrant, elacestrant | Tamoxifen oral often up to about 5 years; fulvestrant IM loading then monthly maintenance |
| Aromatase inhibitors | Anastrozole, exemestane | Daily oral therapy in postmenopausal ER-positive disease |
| Antiandrogens | Flutamide, bicalutamide | Daily oral therapy for prostate-cancer hormone blockade |
Nursing Considerations
- Confirm hormone-receptor context before therapy (for example ER-positive breast disease).
- Monitor CBC, electrolytes, renal and liver function tests, and bone-health surveillance as ordered.
- Monitor for thromboembolic cues (calf pain/swelling, chest pain, sudden dyspnea), especially with tamoxifen pathways.
- For antiandrogen therapy, trend liver enzymes because hepatotoxicity risk is clinically significant.
- Monitor menopausal-type adverse effects and adherence barriers over long treatment duration.
Adverse Effects and Contraindications
- Common effects: Hot flashes, fatigue, weight gain, sexual dysfunction, vaginal dryness, nausea/vomiting, diarrhea.
- Bone effects: Aromatase inhibitors may increase osteoporosis risk.
- Sex-hormone effects in males: Gynecomastia and breast tenderness may occur with antiandrogen pathways.
- Tamoxifen contraindications: Prior DVT/PE and concurrent coumarin-type anticoagulant use.
Health Teaching
- Report fever, calf pain/swelling, chest pain, shortness of breath, and progressive bone pain immediately.
- Maintain hydration and keep scheduled follow-up labs/imaging.
- Report persistent mood changes, severe fatigue, or intolerable vasomotor symptoms for treatment adjustment.
- Avoid unsupervised new supplements or medications due interaction risk.
Related Concepts
- breast-tumor-receptor-profiles - Receptor status determines endocrine-therapy benefit.
- breast-cancer-care - Endocrine therapy is integrated into long-term recurrence-risk reduction.
- prostate-cancer - Antiandrogen therapy in prostate-cancer pathways.
- warfarin - Coumarin anticoagulant interaction and contraindication context with tamoxifen.
Self-Check
- Why are antiestrogens ineffective in hormone-receptor-negative breast cancer?
- Which patients are typical candidates for aromatase inhibitor pathways?
- Which symptom cluster should trigger urgent thromboembolism escalation during tamoxifen therapy?